Zydus Assertio deal: US specialty push, FY27 growth

Why the Assertio move matters for Zydus

Zydus Lifesciences is sharpening its strategy around specialty therapies, biosimilars and innovation-led businesses, with inorganic growth positioned as a key lever. Management has guided for sustained, high-teens revenue growth and stable margins in the current fiscal, and said it continues to see high-teens growth for FY27. The proposed acquisition of Illinois-based Assertio is central to that plan, aimed at creating a high-margin specialty oncology platform in the US. Zydus has framed the deal as a way to secure immediate commercial scale while deepening its presence in the US specialty market. The company discussed these priorities alongside its earnings commentary, signalling an intent to step up investments after what it described as a robust FY26.

What management said on FY27 growth and regional outlook

On the company’s earnings call on May 19, managing director Sharvil Patel said Zydus still sees high-teens growth for FY27. He added that India is expected to continue outperforming the broader market. International markets and the consumer wellness business are expected to sustain strong double-digit growth, as per management commentary. For North America, the company expects steady single-digit gains, citing a high base. This split is important because it highlights Zydus’ view that the next phase of growth will not rely only on US generics, but on multiple engines across geographies and business lines.

The three growth engines Zydus is building

Zydus said it is building three structural growth engines. The first is specialty and rare disease therapies through its Sentinel platform. The second is complex generics and 505(b)(2) products that management believes can scale faster. The third is biosimilars and biologics aimed at global markets.

Management also said the non-generic specialty portfolio is expected to become a meaningful contributor over the next three to five years. It indicated that scale-up should become more visible from FY28 onwards. This is a longer runway than typical generic cycles, and it sets expectations around when specialty revenues could become more material.

Proposed Assertio acquisition and US specialty oncology focus

The proposed acquisition of Assertio is positioned as a step toward building a high-margin specialty oncology platform. Zydus said the transaction would provide immediate commercial scale and deepen its US specialty presence. The rationale aligns with its broader pivot from volume-led generics to specialty-led portfolios where commercial capabilities, lifecycle management and differentiated products matter.

Zydus also said it is exploring mergers, acquisitions and licensing opportunities to bolster its US specialty business, including for its liver therapy saroglitazar. Management aims to launch its first new drug in the US by early 2026, targeting the Primary Biliary Cholangitis (PBC) market.

US generics: launches, filings and key products

In the United States, Zydus said it continues to focus on its generics business with plans for over 30 Abbreviated New Drug Applications (ANDAs) and 25-30 product launches annually. It cited high-value generics such as Revlimid and Asacol HD as part of the strategy. Looking ahead, the company has spoken about a pipeline of 14-15 critical launches in FY27, including complex generics with semi-exclusive or exclusive opportunities, intended to help sustain its US business above a USD 1.0 billion base (excluding exceptional products).

On product timelines, Zydus anticipates launching sitagliptin 505(b)(2) in FY26F and a palbociclib tablet in FY27. It has also cited expected launches such as saroglitazar (FY27) and an Ibrance generic (late FY27 or early FY28).

Specialty and rare disease: 505(b)(2) pipeline and US approvals

“As we pivot towards specialty, we are driving growth through multiple levers,” Patel said, pointing to the expansion of Zydus’ 505(b)(2) pipeline, rare disease portfolio and biologics capabilities. The company disclosed a portfolio of nine 505(b)(2) programs, of which three are approved and launched.

On the US specialty front, Zydus has launched Beizray, described as its first oncology 505(b)(2) product. In rare diseases, it said that in January 2026 it received final USFDA approval for Zycubo (copper histidinate). Zydus described Zycubo as the first and only approved therapy for Menkes disease, an ultra-rare disease.

Biosimilars and biologics: partnerships and runway

Zydus said biosimilars offer a multi-year runway, with global launches and partnerships expected to drive meaningful scale over the next three years and a more material contribution by FY29-30. The company has forayed into the US biosimilars space through an exclusive in-licensing partnership for a pembrolizumab biosimilar. It has also licensed a ranibizumab biosimilar, and has referred to progress such as expected trial results for a Keytruda biosimilar within the year.

Alongside biosimilars, Zydus has highlighted biologics manufacturing expansion through the acquisition of the CDMO business of Agenus in 2025, which included two biologics manufacturing sites in Emeryville and Berkeley. Zydus also said it would partner with Agenus to commercialise molecules in India.

India and consumer wellness: chronic therapies and device push

Within India, Zydus said it is building capabilities in cardiology and nephrology, including acquiring a facility for manufacturing stents and initiating commercialisation of interventional cardiology stents. The company expects its India business to continue outperforming the Indian Pharmaceutical Market (IPM), supported by volumes and new product introductions.

Zydus also said its consumer wellness segment delivered industry-leading double-digit growth in FY25 and expects that trend to persist. Separately, management has highlighted prescription-led growth and a sharper focus on select brands, including identifying 20-25 focus brands and adding 600-700 medical representatives recently. The company has also reported a total MR strength of about 7.5K and total field force strength of about 9K covering 26 divisions.

R&D spending and innovation priorities

Zydus expects R&D spending to remain at about 8% of revenue, with a growing share directed toward new chemical entities (NCEs), biologics and advanced therapies. Key research areas mentioned include cardio-metabolic, inflammation and immunology, neurosciences, oncology and rare diseases, along with biologics such as biosimilar therapeutic proteins and monoclonal antibodies.

On saroglitazar for PBC, the company expects data readout towards the end of calendar year 2025. It has also said an NDA filing with the USFDA is expected in 2026, and that it plans to commercialise independently if results are positive.

Key guidance and milestones at a glance

Market impact and why the strategy is changing

Zydus’ guidance implies a growth model that is less dependent on a single geography or a single business line. With North America guided to single-digit growth, the company is highlighting India outperformance, strong double-digit growth in international and consumer wellness, and an expanding specialty and biosimilars pipeline to sustain consolidated momentum. The proposed Assertio acquisition is presented as a way to accelerate US specialty scale rather than relying only on filing-and-launch cycles.

The emphasis on 505(b)(2) and rare disease products also signals an attempt to build portfolios with differentiated regulatory pathways and potentially more durable economics. At the same time, Zydus’ stated R&D allocation of around 8% of revenue indicates it intends to fund innovation while maintaining stable margins, as guided. Any execution will be reflected in whether the company can deliver the stated timelines for saroglitazar, US specialty expansion and biosimilar scale-up.

Conclusion

Zydus Lifesciences is pairing its high-teens FY27 growth ambition with a clearer pivot toward specialty therapies, rare disease products, biosimilars and innovation-led R&D. The proposed Assertio acquisition is positioned as a strategic step to build a high-margin US specialty oncology platform with immediate commercial scale. Over the next 12 to 24 months, investors are likely to track progress on US launch cadence, the saroglitazar PBC program milestones, and the company’s stated biosimilar partnerships and launch runway through FY29-30.